Scientists map genetic blueprint of lung cancer resistance
NCT ID NCT05219162
Summary
This study aimed to understand why advanced lung cancer stops responding to the first-line treatment osimertinib. Researchers analyzed genetic changes in tumor tissue and blood samples from 182 patients whose cancer had progressed despite treatment. The goal was to identify patterns that could help doctors choose better follow-up treatments for future patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100210, China
-
Research Site
Changsha, 410013, China
-
Research Site
Chengdu, 610014, China
-
Research Site
Dalian, 116023, China
-
Research Site
Foshan, 528000, China
-
Research Site
Fuzhou, 350014, China
-
Research Site
Harbin, 150081, China
-
Research Site
Hefei, 230001, China
-
Research Site
Hefei, 230601, China
-
Research Site
Linhai, 317000, China
-
Research Site
Luoyang, 471003, China
-
Research Site
Rizhao, 276826, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Taizhou, 225300, China
-
Research Site
Tianjin, 300060, China
-
Research Site
Zhengzhou, 450000, China
Conditions
Explore the condition pages connected to this study.